Usnarska-Zubkiewicz L, Augustyniak-Bartosik H, Zubkiewicz-Kucharska A, Knysz B. An asymptomatic course of SARS-CoV-2 infection in a patient with 3 different neoplasms and treated with bortezomib: a coincidence or new therapeutic possibility? Pol Arch Intern Med. 2021; 131: 747-748. doi:10.20452/pamw.16013

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Table S1. Selected laboratory test results of the presented patient

At MM diagnosis								
Myelogram	Intermediate bone marrow density, with 20% of plasmocytes and plasmoblasts arranged in nests and the erythroblastic system with normoblastic renewal, was clearly reduced. No cytogenetic testing has been done.							
Serum immunofixation	Lambda-type free light chains (highly saturated band) – present							
Serum immunoglobulins	IgG 13 g/l	IgA 0.8	9 g/l	IgM 0.2 g/l				
Serum free light chains (sFLC)	sFLC kappa 18.8 mg/l		sFLC lambda 19,700 mg/l					
Urine protein immunofixation	Lambda chains (highly saturated band) – present	Glomerular proteins: albumin and transferrin (slightly		Tubular proteins – not found				

			saturated bands) –					
			present					
Other	Hb 9.7 g/dl		WBC 15.02*10 ³ /μl		Corrected calcium 12.8 mg/dl			
At SARS-COV-2 diagnosis								
Neutrophils 5.12*10 ³ /μl		Lymphocytes 1.72*10 ³ /μl		Monocytes 0.69*10 ³ /μl				
CD4 ⁺ T cell count 557 cells/μl								
LDH 313 U/I								

CD4 – cluster of differentiation 4; Ig – immunoglobulin; Hb – haemoglobin; LDH – lactate dehydrogenase; MM – multiple myeloma; sFLC – serum free light chains; SARS-COV-2 – severe acute respiratory syndrome 2; WBC – white blood cells count